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Purpose: Early hypopharyngeal squamous cell carcinoma (HPSCC) is a rarely diagnosed disease, for which the optimal treatment 
has not been defined yet. We assessed patterns of failure and outcomes in early HPSCC treated with various therapeutic approaches 
to identify its optimal treatment.
Materials and Methods: Thirty-six patients with stage I (n = 10) and II (n = 26) treated between January 1992 and March 2014 
were reviewed. Patients received definitive radiotherapy (RT) (R group, n = 10), surgery only (S group, n = 19), or postoperative RT 
(PORT group, n = 7). All patients in both the R and PORT groups received elective bilateral neck irradiation. In the S group, 7 patients 
had ipsilateral and 8 had bilateral dissection, while 4 patients had no elective dissection.
Results: At a median follow-up of 48 months, the 5-year locoregional control (LRC) rate was 65%. Six patients had local failure, 
1 regional failure (RF), 3 combined locoregional failures, and 2 distant failures. There was no difference in 5-year LRC among the R, 
S, and PORT groups (p = 0.17). The presence with a pyriform sinus apex extension was a prognosticator related to LRC (p = 0.01) in 
the multivariate analysis. Patients with a bilaterally treated neck showed a trend toward a lower RF rate (p = 0.08). 
Conclusion: This study shows that patients with early stage HPSCC involving the pyriform sinus apex might need a tailored 
approach to improve LRC. Additionally, our study confirms elective neck treatment might have an efficacious role in regional 
control.
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Introduction
Early-stage hypopharyngeal squamous cell carcinomas 
(HPSCCs) (stage I or II) have been reported in less than 20% 
of patients with HPSCC due to advanced primary disease and 
extensive regional lymph node involvement before diagnosis 
because of the nonspecific nature of the early symptoms until 
extension to adjacent structures and abundant lymphatic 
drainage of the hypopharynx [1,2]. 
Because of the rarity of early HPSCC, few reports regarding 
treatment outcomes of early HPSCC have been published. In 
addition, owing to uncertainty about optimal treatment, a 
variety of treatment options have been considered for patients 
with early-stage HPSCC to preserve the larynx in clinical 
practice. Treatment options include endoscopic removal, open 
partial laryngopharyngectomy, total laryngectomy with partial 
pharyngectomy, and definitive radiotherapy (RT) [3]. National 
Comprehensive Cancer Network (NCCN) Guidelines [4] suggest 
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definitive RT or partial laryngopharyngectomy with ipsilateral 
or bilateral neck dissection for early-stage HPSCC. Factors that 
affect treatment options included the tumor extent, volume 
of the tumor, patient preference, patient age, comorbidity, 
physician experiences, and physician and institutional 
preferences.
At our institution, patients with early HPSCC are treated 
with either RT and surgery alone or a combined modality with 
surgery followed by postoperative RT. We assessed patterns 
of failure and outcomes in patients with early HPSCC who 
were treated with different therapeutic approaches in order to 
determine the optimal treatment strategy. 
Materials and Methods
1. Study population
We identified 46 consecutive patients diagnosed at our 
institution between January 1992 and March 2014. Inclusion 
criteria were as follows: 1) patients with pathologically 
confirmed hypopharyngeal squamous cell carcinoma; 2) 
patients with newly diagnosed and previously untreated 
hypopharyngeal cancer; and 3) patients with T1/2N0M0 
staging (American Joint Committee on Cancer [AJCC] 
staging). Three patients with synchronous malignancy, 2 with 
pathologically proven mucoepidermoid carcinoma, and 1 
with myxoid liposarcoma were excluded. Four patients who 
underwent treatment at other institutions were excluded 
because there was limited follow-up information that could 
be used to assess the clinical outcomes. A total of 36 patients 
were analyzed in this retrospective study. 
All patients underwent pretreatment evaluation, physical 
examination with laryngoscopy, and radiologic imaging 
such as computed tomography (CT) and magnetic resonance 
imaging (MRI) of the head and neck region. All patients were 
staged according to the 2010 AJCC TNM staging system 
(7th edition). There were 10 patients with stage I (tumor 
limited to one subsite of the hypopharynx and 2 cm or less 
in greatest dimension), and 26 with stage II (tumor invading 
more than one subsite of the hypopharynx or an adjacent 
site, or measuring more than 2 cm but not more than 4 cm in 
the greatest dimension without fixation of the hemilarynx). 
Patients treated with definitive RT were staged clinically based 
on physical examination and images, while those treated with 
surgery or surgery followed by postoperative RT were staged 
pathologically based on surgical pathologic specimens. The 
definition of the resection margin was based on pathologic 
reports. Achievement of less than 5 mm margins including 
tumor cells abutting the resection margins was defined as 
a close margin, and extension of tumor cells was defined as 
a positive margin. All other instances were defined as clear 
margins. 
Among 36 patients, 10 were treated with definitive RT (R 
group), 19 with surgery only (S group), and 7 with surgery 
followed by postoperative RT (PORT group).
2. Treatment 
Each treatment option was selected by the multidisciplinary 
head and neck cancer team according to age, medical co-
morbidities, and patients’ and physicians’ preferences. With 
the upfront approach, the location of the tumor was an 
important factor. For example, 2 patients with tumors located 
in the post-cricoid area, where difficult surgical techniques 
were required, were treated with definitive RT, and of the 14 
patients with tumors in the posterior pharyngeal wall that 
were able to be resected relatively easily, all underwent surgery 
except for one patient who underwent definitive RT according 
to the patient’s preference. Adjuvant treatments following 
surgery were determined based on pathologic reports. Positive 
or close resection margins were preferentially considered as 
determinants for adjuvant RT. 
The S group (n = 19) included mass excision (n = 2), partial 
pharyngectomy (n = 11), total laryngectomy with partial 
pharyngectomy (n = 4), and total pharyngolaryngectomy (n 
= 2). In the R group (n = 10), 9 patients underwent CT-based 
RT planning with either 3-dimensional conformal RT (3D-CRT, 
n = 3) or intensity-modulated RT (IMRT) (n = 6), and only one 
patient in the R group underwent 2D-based RT. The treatment 
plan with 2D-based RT encompassed the whole hypopharynx 
using two lateral beams for 70.2 Gy with a fraction dose of 
1.8 Gy and covered the bilateral neck level II to SCL for 45 Gy 
with a fraction dose of 1.8 Gy. For all other patients treated 
with 3D-CRT or IMRT, the gross tumor volume (GTV) at the 
primary site plus generally 3 mm margins was defined as the 
planning target volume of the primary site (PTVp), which was 
treated with a median total dose of 68.4 Gy (range, 60.8 to 
70.2 Gy) and a median fraction dose of 2.1 Gy (range 1.8 to 2.3 
Gy). For all patients in the R group, the clinical target volume 
of the neck node area (CTVn) was defined as the bilateral neck 
level II to IV, and in 2 patient, the bilateral retropharyngeal 
nodal regions were added to the CTVn. After delineating CTVn, 
the additional 3 mm margins were added to planning target 
volume of the neck node area (PTVn) (Fig. 1 ). A median total 
dose of 54 Gy (range, 30.6 to 55.8 Gy) with daily fraction doses 
of 1.8 Gy was prescribed for the PTVn. For the PORT group (n 
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= 7), 6 patients underwent partial pharyngectomy and one 
patient underwent mass excision. Six patients underwent CT-
based RT planning with either 3D-CRT (n = 5) or IMRT (n = 1), 
and 1 patient underwent 2D-based RT. 2D-based RT planning 
covered the postoperative tumor bed with a total dose of 54 
Gy and a daily fraction dose of 1.8 Gy and the upper neck 
levels II to III were treated with a total dose of 45 Gy and a 
daily fraction dose of 1.8 Gy. In 6 patients with CT-based RT 
planning, the PTVp was defined as the postoperative tumor 
bed plus 3 mm margins and was prescribed a median total 
dose of 63 Gy (range, 59.4 to 66.6 Gy) with a daily fraction 
dose of 1.8 Gy (range, 1.8 to 2.0 Gy). The PTVn was defined as 
the bilateral neck levels II to IV, and in 1 patient, the bilateral 
retropharyngeal nodal regions were added to the PTVn. A 
median total dose of 45 Gy (range, 41.4 to 54 Gy) with a daily 
fraction doses of 1.8 Gy (range, 1.8 to 2.0 Gy) was prescribed 
for the PTVn.
Treatment-related toxicities were assessed using the 
Common Terminology Criteria for Adverse Events (CTCAE, ver. 
4.03) based on limited medical records. Treatment toxicities 
were not fully accessible to the entire cohort, particularly for 
the S group, for which there was limited information. Only 8 
patients in the S group were recorded as having treatment 
toxicities. Information on acute toxicities related to RT was 
available for 17 patients of the R and PORT groups. Late 
toxicities were assessed in only 11 patients.
3. Statistical analysis
The primary endpoint of this study was the locoregional 
control rate (LRC), which is defined as complete and persistent 
regression of the tumor in the primary site or regional lymph 
nodes. The LRC was calculated from the start of treatment 
to the date of locoregional failure diagnosis or date of last 
follow-up. The Kaplan-Meier method was used to estimate 
the LRC rate. The survival curves were compared using the 
log-rank test. To determine the effects of distinct prognostic 
factors on survival, multivariate analysis was performed using 
a Cox’s regression model. Differences in patient characteristics 
of the pyriform sinus (PS) extension and elective neck 
treatment were assessed using the Pearson χ²-test. Differences 
in treatment options were assessed using the Fisher exact 
test. In all statistical analyses, p < 0.05 was considered to be 
significant. Statistical analysis was carried out using IBM SPSS 
ver. 20 (IBM, Armonk, NY, USA).
Results
1. Patient and tumor characteristics
The median follow-up period for the entire cohort was 48 
months (range, 5 to 164 months). Median age at diagnosis 
was 65 years (range, 46 to 85 years) and most patients were 
men (91.7%). Twenty-seven patients (75%) were ex-smokers 
with a median of 30 pack-years. The primary site of the tumor 
was the PS in 20 patients (55.6%), posterior pharyngeal wall 
in 14 patients (38.9%), and the post cricoid area in 2 patients 
(5.6%). The PS apex extension was identified through a 
laryngoscope in 14 patients (38.9%). The median tumor size 
was 2.3 cm (range, 0.5 to 4.0 cm). There was no statistically 
significant difference in patient and tumor characteristics 
among the treatment groups. The baseline patient and tumor 
characteristics are shown in Table 1.
2. Treatment characteristics
In the S group, open surgery was performed in 16 patients 
Fig. 1. Computed tomography images 
showing an example of radiotherapy planning 
with intensity-modulated radiotherapy. A 
72-year-old male patient was diagnosed 
with early hypopharyngeal squamous cell 
carcinoma involving the left aryepiglottic 
fold without pyriform sinus apex extension. 
The planning target volume for gross tumor 
(PTVp) covered primary site with margins. 
The planning target volume for elective neck 
node area (PTVn) covered bilateral neck level 
II to IV and retropharyngeal nodal regions 
with additional margins. The prescribed doses 
to PTVp and PTVn were 66 Gy in 2.2 Gy and 
45 Gy in 1.8 Gy, respectively.
A B
C
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(84.2%) and laser or trans-oral surgery (TORS) in 3 patients 
(15.8%). In the PORT group, 3 patients (42.9%) underwent 
open surgery, and 4 (57.1%), TORS or laser surgery. There was a 
trend toward higher prevalence of minimally invasive surgery 
such as laser or TORS in the PORT group than in the S group 
(p = 0.06). The resection margin (RM) status was statistically 
different between both groups that underwent surgery (S 
group and PORT group) (p = 0.03). A close or positive RM was 
observed in 6 patients (31.6%) in the S group and 6 (84.7%) in 
the PORT group.
All patients in the R group underwent bilateral elective neck 
treatment. In the S group, no elective neck treatment was 
performed in 4 patients (21.1%); ipsilateral neck dissection was 
performed in 7 patients (36.8%), and bilateral neck dissection 
in 8 patients (42.1%). In the PORT group, ipsilateral elective 
neck dissection was performed in 3 patients (42.9%), and 
bilateral neck dissection in 3 patients (42.9%); no elective neck 
dissection was performed in 1 patient. Patients in the PORT 
Table 1. Patient characteristics
Characteristic Total (n = 36) R group (n = 10) S group (n = 19) PORT group (n = 7) p-value
Age (yr)
 <65
 ≥65
Sex
 Male
 Female
Smoking history
 None
 Ex-smoker
 Unknown
 Pack-year
Alcohol history
 None
 Social
 Heavy
 Unknown
ECOG performance status
 0–1
 2–4
Subsite
 PS
 PPW
 PC
T stage
 T1
 T2
Median volume (mL)
PS apex
 Free
 Extension
Tumor differentiation
 WD/MD
 PD
Resection margin
 Clear
 Close/positive
 65 (46–85)
 17 (47.2)
 19 (52.8)
 33 (91.7)
 3 (8.3)
 7 (19.4)
 27 (75)
 2 (5.6)
 30 (0–90)
 5 (13.9)
 23 (63.9)
 7 (19.4)
 1 (2.8)
 34 (94.4)
 2 (5.6)
 20 (55.6)
 14 (38.9)
 2 (5.6)
 10 (27.8)
 26 (72.2)
 6.6 (2.6–12.8)
 22 (61.1)
 14 (38.9)
 33 (91.7)
 3 (8.3)
-
-
 69 (46–83)
 4 (40.0)
 6 (60.0)
 9 (90.0)
 1 (10.0)
 2 (20.0)
 8 (80.0)
 0 (0)
 28 (0–70)
 0 (0)
 8 (80.0)
 2 (20.0)
 0 (0)
 10 (100)
 0 (0)
 7 (70.0)
 1 (10.0)
 2 (20.0)
 3 (30.0)
 7 (70.0)
 6.4 (3.6–8.21)
 8 (80.0)
 2 (20.0)
 8 (80.0)
 2 (20.0)
-
-
 65 (53–85)
 9 (47.4)
 10 (52.6)
 17 (89.5)
 2 (10.5)
 3 (15.8)
 15 (78.9)
 1 (5.3)
 30 (0–80)
 3 (15.8)
 10 (52.6)
 5 (26.3)
 1 (5.3)
 17 (89.5)
 2 (10.5)
 10 (52.6)
 9 (47.4)
 0 (0)
 6 (31.6)
 13 (68.4)
 6.2 (2.6–12.8)
 11 (57.9)
 8 (42.1)
 18 (94.7)
 1 (5.3)
 13 (68.4)
 6 (31.6)
 61 (49–80)
 4 (57.1)
 3 (42.9)
 7 (100)
 0 (0)
 2 (28.6)
 4 (57.1)
 1 (14.3)
 20 (0–90)
 2 (28.6)
 5 (71.4)
 0 (0)
 0 (0)
 7 (100)
 0 (0)
 3 (42.9)
 4 (57.1)
 0 (0)
 1 (14.3)
 6 (85.7)
 6.4 (3.6–8.2)
 3 (42.9)
 4 (57.1)
 7 (100)
 0 (0)
 1 (14.3)
 6 (85.7)
0.78
0.67
0.68
0.41
0.39
0.08
0.67
0.28
0.48
0.03
Values are presented as median (range) or number (%).
R, definitive radiotherapy; S, surgery; PORT, surgery followed by adjuvant radiotherapy; ECOG, Eastern Cooperative Oncology Group; PS, 
pyriform sinus; PPW, posterior pharyngeal wall; PC, post cricoid area; WD, well-differentiated; MD, moderate-differentiated; PD, poorly 
differentiated.
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group were treated with elective irradiation to bilateral neck 
nodes. 
3. Patterns of failure
With a median time to recurrence of 10.5 months (range, 
5.9 to 59.3 months), among all patients, 12 patients (33.3%) 
developed failures, including 6 with local failure (LF), 1 with 
regional failure (RF), 3 with combined loco-regional failures 
(LRFs), and 2 with distant metastases (DM). The PORT group did 
not have any treatment failures but the R group experienced 
failures in 4 cases, of which 3 were LF and 1 was DM. The S 
group had 8 treatment failures (42.1%) including 3 LF, 1 RF, 3 
combined LRF, and 1 DM. 
In patients with LF, RF and LRF, salvage treatment and 
outcomes are summarized in Table 2. Except for 1 patient 
who refused, 9 patients underwent salvage treatment. 
Of these patients, 3 underwent salvage surgery alone; a 
supraglottic partial laryngectomy was performed in 1 patient, 
and mass excision in 2 patients. Salvage RT was performed 
in 1 patient and concurrent chemoradiotherapy (CRT) in 2 
patients. Three patients underwent salvage surgery followed 
by adjuvant treatment; 2 patients had a neck dissection with 
postoperative RT; and 1 patient had mass excision followed 
by neck node RT. Except for 1 patient with primary tumor 
bed and retropharyngeal node recurrence, 8 patients showed 
a complete response after salvage treatment. The 5-year 
ultimate LC after salvage treatment was 79.8%. 
4. Locoregional/regional control and prognostic factors
The overall 5-year LRC was 64.6% (Fig. 2). There was no 
difference in the 5-year LRC among the 3 groups (R, S, Ta
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Fig. 2. Locoregional control rate (LRC) for the entire cohort.
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Table 3. Univariate and multivariate analysis for association of factors with LRC
Univariate analysis Multivariate analysis
5-yr LRC (%) p-value HR 95% CI p-value
Age (yr)
 <65
 ≥65
Subsite
 PS
 PPW
 PC
T stage
 T1
 T2
PS apex
 Free
 Extension
Tumor differentiation
 WD/MD
 PD
Treatment option
 S group
 R group
 PORT group
Neck treatment
 None/ipsilateral
 Bilateral
80.2
49.0
57.1
79.1
50.0
60.0
66.9
75.6
37.6
61.4
100
51.9
66.7
100
56.8
71.8
0.41
0.24
0.14
0.09
0.29
0.17
0.68
-
-
-
-
-
Ref.
0.36
Ref.
7.10
-
-
Ref.
0.68
0.00
Ref.
1.67
-
-
-
-
-
-
0.09–1.40
-
1.50–33.61
-
-
-
0.12–3.76
0.00–NA
-
0.33–8.30
-
-
0.14
0.01
-
-
0.66
0.97
-
0.54
LRC, locoregional control rate; HR, hazard ratio; CI, confidence interval; PS, pyriform sinus; PPW, posterior pharyngeal wall; PC, post 
cricoid area; WD, well-differentiated; MD, moderate-differentiated; PD, poorly differentiated; S, surgery only; R, definitive radiotherapy; 
PORT, surgery followed by adjuvant radiotherapy; NA, not available. 
Fig. 3. Locoregional control rate (LRC) according to the treatment approach (A) and the pyriform sinus (PS) apex extension (B). R, 
definitive radiotherapy; S, surgery only; PORT, surgery followed by adjuvant radiotherapy.
LR
C
Months
12
20
40
60
80
100
0
0 24 36 6048
A
S group
PORT group
R group
p = 0.17
LR
C
Months
12
20
40
60
80
100
0
0 24 36 6048
B
PS apex extension
PS apex free
p = 0.09
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and PORT 66.7%, 51.9%, and 100%; p = 0.17) (Fig. 3A). 
Furthermore, there was no statistically significant predictive 
factor of LRC based on the univariate analysis (Table 3). The 
PS apex extension showed a borderline significance related to 
5-year LRC in the univariate analysis (75.6% vs. 37.6%; p = 
0.09) (Fig. 3B). When performing a multivariate analysis using 
factors with a p-value of <0.20 on univariate analysis, the LRF 
in patients with a PS apex extension was significantly higher 
(hazard ratio [HR], 7.10; 95% confidence interval [CI], 1.50 to 
33.61; p = 0.01) (Table 3, Fig. 4) than that in patients with an 
intact PS apex considering the T stage, treatment modality, and 
elective neck node treatment. 
Patients with a bilaterally treated neck had a lower RF rate 
compared to untreated or ipsilateral treated patients (4% 
vs. 27%; p = 0.08). Of the 4 nodal recurrent events, 1 nodal 
failure was observed in a patient initially treated with bilateral 
neck dissection, and 3 in patients with initially untreated neck 
nodes; 1 patient was initially treated without neck dissection, 
and 2 patients with contralateral neck node failures were 
initially treated with ipsilateral neck node dissection.
5. Toxicity
Fourteen patients (38.9%) experienced more than grade 
3 treatment related toxicities. There was no statistically 
significant difference in the proportion of patients who 
experienced grade 3 toxicities (p = 0.72), which included 
3 patients in the R group, 8 patients in the S group, and 3 
patients in the PORT group. 
Acute toxicities of grade 3 or higher including wound 
dehiscence and fistula formation after surgery were observed 
in 6 patients of the S group and in 3 patients of the PORT 
group. All patients who underwent RT (R or PORT group) 
experienced acute grade 1 or 2 oral mucositis; however, all 
patients recovered within 1 month after RT. One patient in 
the R group underwent both tracheostomy and gastrostomy 
due to grade 4 pharyngitis and esophagitis. Scheduled RT 
was interrupted due to grade 3 generalized weakness in 
another patient in the R group who finished RT early after 27 
treatment sessions. Late toxicities of grade 3 or higher stenosis 
or pharyngitis was observed in 11 patients; 2 patients in the 
R group, 4 patients in the S group, and 2 patients in the PORT 
group (20.0% vs. 28.6% vs. 21.1%; p = 1.00). These patients 
underwent delayed gastrostomy or tracheostomy. 
Discussion and Conclusion
In this study, we assessed LRC and patterns of treatment 
failure in patients with early-stage HPSCC treated with various 
therapeutic approaches. The previous studies reported that the 
LRC rate of early-stage HPSCC was 60% to 88% when treated 
either by surgery [5-7] or by definitive RT [8-13]. We found 
that the 5-year LRC rate of these patients was 65%, which 
was comparable to other studies. We also analyzed patterns 
of LRF, including 6 cases of LF, 1 of RF, and 3 of combined 
LRF. Nakamura et al. [8] evaluated 115 patients with stage 
I-II HPSCC treated with RT with or without chemotherapy. 
This multi-institutional study reported that the LRC rate was 
78%, with 25 cases of LF, 9 of RF, and 5 of combined failures. 
Sato et al. [12] reported a 56% 5-year LRC rate in 33 stage I-II 
HPSCC patients treated with either RT or CCRT. Among the 33 
patients, LRF occurred in 13 patients: 8 had LF, 1 had RF, and 
3 had combined failures. Kuo et al. [7] reported 53 patients 
treated with either open partial laryngopharyngectomy or 
endoscopic laser microsurgery had a 5-year LRC of 71%. Of the 
53 patients, 13 experienced failures (8 LF and 5 RF).
Furthermore, the 5-year LRC rate in early-stage HPSCC 
Fig. 4. Computed tomography images showing 
an example of hypopharyngeal squamous cell 
carcinoma (HPSCC) with a pyriform sinus (PS) apex 
extension (tumor mass was marked by a dashed line). 
A 66-year-old male patient was diagnosed with early 
HPSCC involving right PS and right aryepiglottic fold. 
The patient showed a clear resection margin after 
total laryngectomy and partial pharyngectomy with 
bilateral neck dissection. After 6 months, local failure 
at the primary tumor bed developed. He underwent 
concurrent chemoradiotherapy. At 23 months after 
the local failure, hematogenous lung metastasis 
developed, and the patient died of disease.
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with PS apex extension was 37.6% compared to 75.6% in 
tumors without apex extension (p = 0.09). However, it should 
be interpreted cautiously in terms of both a small number of 
patients and borderline significance. There was no difference 
in LRC rate among treatment groups whether with PS apex 
extension or not. In patients with PS apex extension, LRF 
occurred in 5 patients: 4 in the S group (50%), 1 in the R 
group (50%). In patients without PS apex extension, 3 patients 
in the S group (27%) and 2 patients in the R group (25%) 
experienced LRF and there was no statistically significant 
difference.
We also found that PS apex extension was a significant 
prognosticator of LRC in multivariate analyses. Several 
previous reports have confirmed the correlation between PS 
apex extension and LRC [13-15]. Rabbani et al. [13] reported 
that borderline significance of PS apex involvement correlated 
to local control (79% vs. 90%, p = 0.11) in 84 HPSCC patients. 
Pameijer et al. [14] reported that the bulky apex disease 
significantly influenced the local control rate (p = 0.03) in 
HPSCC treated with definitive RT. Amdur et al. [15] reported 
on the treatment outcomes of 101 HPSCC patients with 
T1 (n = 22) and T2 (n = 79) cancer who were treated with 
RT with/without planned neck dissection. Patients with T1 
HPSCC involving the PS apex showed significantly reduced LC 
compared to those without PS apex extension (33% vs. 100%; 
p = 0.02). 
In the current study, 85% (12 of 14) patients with a 
PS apex extension underwent surgery. Two patients with 
positive surgical margin who underwent minimally invasive 
surgery were treated with adjuvant RT, and did not show LRF 
during follow-up periods of 30 and 13 months, respectively. 
Additionally, two other patients with positive margins who 
underwent adjuvant RT lived without disease until the last 
follow-up (132.7 and 55.5 months, respectively). Conversely, 
4 of 8 (50%) patients with a PS extension who underwent 
surgery alone experienced LRF, even in case of negative 
surgical margins. This implies that appropriate adjuvant RT 
encompassing the primary tumor bed and elective neck lymph 
nodes should be considered in early HPSCC patients with PS 
apex extension. Especially, adjuvant RT could play a critical role 
in patients with preoperatively diagnosed PS apex extension 
because the probability of positive surgical margins increases 
in the era of minimally invasive surgery.
There was no RF in patients of R or PORT groups who 
received RT covering the bilateral neck nodal chain, and only 
one case (12.5%) of RF in the S group underwent bilaterally 
neck dissection. A favorable 5-year LRC was shown in our 
study, although there was not a statistically significant 
difference in the bilaterally treated neck group compared 
to the ipsilateral or untreated neck group (56.8% vs. 71.8%; 
p = 0.68), with no increase in rates of late toxicity. In this 
study, it was presumed that RT could play a role in elective 
neck node treatment to manage microscopic lymphatic 
spread in patients treated with or without surgery. Owing to 
the rich lymphatic drainage of the hypopharyngeal region, 
occult nodal metastases including micro-metastases and 
contralateral neck metastasis were observed to range from 
30% to 40% in clinically N0 HPSCC [16,17]. For these patients, 
micro-metastases cannot be neglected due to the abundant 
lymphatic drainage; thus, omission of neck treatment leaves 
the probability of occult nodal failure [18], which correlates 
with poor LRC and ultimately poor distant control and overall 
survival [19]. Yoshimura et al. [20]  showed the importance 
of locoregional field RT by reporting 77 patients with stage 
I or II hypopharyngeal cancer (HPC)  treated with definitive 
RT either with or without chemotherapy. In this study, 66 
of 77 patients (85%) were treated with locoregional RT that 
electively encompassed the bilateral neck and nodal regions. 
Patients treated with a locoregional field had a statistically 
significant better 5-year LC with laryngeal voice preservation 
in 73% compared to 42% among patients treated with a 
local field. Though locoregional RT could achieve a favorable 
outcome, treatment-related toxicities such as xerostomia 
should be considered due to the extent of the irradiated field. 
Comparable outcomes with less toxicity are expected in those 
treated in the era of IMRT [21,22]. In a meta-analysis of 871 
patients treated with 2D-based RT or 3D-CRT versus IMRT 
[21], IMRT was found to reduce the incidence of grade 2–4 
xerostomia (HR, 0.76; 95% CI, 0.66 to 0.87; p < 0.01) without 
compromising LRC or OS. A randomized study [22] also showed 
that IMRT significantly reduced the incidence and severity 
of xerostomia. Therefore, RT with advanced IMRT could be a 
tolerable treatment option in early HPC resulting in adequate 
coverage of bilateral neck node with reduced toxicities.
However, there is a still an issue of the extent of elective 
neck node treatment [23]. We observed 2 patients with 
contralateral RF, which accounted for 25% of those initially 
treated with ipsilateral neck dissection in the S group. The 
current surgical approaches recommend selective neck 
dissection of cervical lymph node level II to IV to prevent 
occult nodal failure [24]. A few studies have recommended 
elective contralateral neck treatment for high-risk patients, 
namely those with tumor involving both the medial wall of 
the PS [25,26] and the posterior pharyngeal wall [27]. Future 
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research will be necessary to identify the prognostic factor(s) 
related to regional control in terms of optimal neck treatment.
In general, adjuvant RT improved LRC after surgery with 
adverse pathologic features, especially those involving RM [28]. 
Of the 12 patients with close or positive resection margins, 6 
patients underwent adjuvant RT and showed no failure. Thus 
it can be assumed that adjuvant RT can prevent upcoming 
failures in patients with unfavorable postoperative pathologic 
features, although there was no significant statistical 
difference in failure. The addition of adjuvant RT after surgery 
achieved an excellent LRC rate. Interestingly, although the 
PORT group had more adverse surgical RMs than the S group 
(84.7% vs. 31.6%; p = 0.03), there was no LF, RF and LRF in 
the PORT group compared to the S group. In addition, while 1 
patient (16.7%) out of 6 patients with total laryngectomy or 
total pharyngolaryngectomy had positive margins, 11 patients 
(55.0%) out of 20 patients with partial pharyngectomy or 
mass excision had close/positive margins. Organ conservation 
surgery, such as partial pharyngectomy and minimally invasive 
approaches, were likely to result in close or positive RMs 
due to the high predilection of submucosal tumor spread of 
HPSCC. Regarding the current trend with declining use of open 
or extensive surgery [29], appropriate adjuvant RT should be 
considered with elective neck node irradiation to yield a good 
LRC.
The findings of this study should be interpreted with 
an understanding of the following limitations. Due to the 
low prevalence of early HPSCC, the data of this study was 
comprised of a relatively small number of patients. The small 
sample size might have limited the possibility to detect 
statistically meaningful differences. Since our study did 
not include pathologically proven node positive patients in 
clinically node negative patients after surgery, it is difficult to 
compare the treatment outcomes directly between R and S 
or PORT. Therefore, we were not able to suggest statistically 
proven better treatment modality among S, R, and PORT. 
Despite the low number of patients, follow-up time for 
each patient was adequate to assess LRC according to each 
treatment. It is possible that the differences in the treatment 
approach over the periods of the study, such as a surgical 
approach or radiotherapy treatment technique (3D-CRT, IMRT), 
could result in a misinterpretation. Further investigation 
with large cohort is needed to evaluate the appropriate 
treatment option in early stage HPSCC. It should also be 
noted that clinical and functional data for treatment-related 
toxicities were not available. This could be possible source of 
underestimating toxicities. 
In conclusion, we found that early stage HPSCC could 
achieve a favorable LRC by each treatment modality with 
optimized management of the elective neck nodal region. 
Our study suggests that early-stage HPSCC with a PS apex 
extension might require intensive locoregional treatment for 
improving LRC; for example, adjuvant RT after surgery based 
on risk factors. Thus it can be presumed that elective neck 
treatment for early-stage HPSCC might have a role in regional 
control.
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